Ono Pharmaceutical Co. (OTCMKTS:OPHLF) Short Interest Up 51.3% in July

Ono Pharmaceutical Co. (OTCMKTS:OPHLF) saw a significant growth in short interest during the month of July. As of July 31st, there was short interest totaling 3,578,303 shares, a growth of 51.3% from the July 15th total of 2,365,389 shares. Based on an average trading volume of 483 shares, the days-to-cover ratio is currently 7,408.5 days. Approximately 0.8% of the company’s stock are sold short.

Wall Street Analyst Weigh In

Separately, Zacks Research upgraded shares of Ono Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Strong Buy”.

Ono Pharmaceutical Price Performance

Ono Pharmaceutical stock remained flat at $14.71 during midday trading on Tuesday. Ono Pharmaceutical has a 1-year low of $10.27 and a 1-year high of $18.67. The company has a quick ratio of 2.56, a current ratio of 3.02 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $6.91 billion, a P/E ratio of 14.01 and a beta of 0.33. The stock’s fifty day simple moving average is $14.39 and its two-hundred day simple moving average is $14.80.

About Ono Pharmaceutical

Ono Pharmaceutical Co, Ltd., founded in 1717 and headquartered in Osaka, Japan, is a research‐based pharmaceutical company specializing in the discovery, development and marketing of innovative therapies. With origins as a traditional pharmacy, Ono has grown into a global biopharmaceutical entity focused on delivering new treatment options across several therapeutic areas, including oncology, immunology, cardiovascular and antiviral diseases. The company conducts comprehensive research programs spanning early drug discovery through to clinical development.

One of Ono’s most recognized products is the immune checkpoint inhibitor nivolumab, marketed in collaboration with Bristol-Myers Squibb under the trade name Opdivo.